Slide 1: Investor Presentation with Q2 2026 Financial Highlights
INVESTOR PRESENTATION WITH Q2 2026 FINANCIAL HIGHLIGHTS
Slide 2: Forward Looking Statement Disclaimer
Forward Looking Statement Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This presentation includes information, statements, beliefs, and opinions which are forward-looking, and which reflect current estimates, expectations, and projections about future events, referred to herein
Slide 3: We're on a Mission to Improve Lives Through the Power of Cannabis
We’re on a Mission to Improve Lives Through the Power of Cannabis. 3
Slide 4: Our Growth Strategy
OUR GROWTH STRATEGY • Grow MariMed’s portfolio • Expand wholesale • Increase customer lifetime of leading cannabis brands penetration and asset-light value through retail Scale Distribution Expand the Brand through innovation, market expansion through engagement, loyalty Deepen Consumer category exp
Slide 5: MariMed by the Numbers
MARIMED BY THE NUMBERS $160M 900+ 9 13 2025 REVENUE EMPLOYEES STATES DISPENSARIES 7 52M+ 670+ 5 FACILITIES Cultivation and POPULATION WHOLESALE BRANDS Production ACCOUNTS #1 Edible & #5 Beverage ~526K+ sq ft (inc. PA facility under Mgmt.) ~$11b Across Core States TAM 5 Data as of August 2026
Slide 6: Why MariMed Wins
WHY MARIMED WINS Leading Cannabis CPG Platform Scalable Wholesale Engine Retail + Loyalty Ecosystem • #1 edible brand across core markets • 85% dispensary penetration • 415K loyalty members • Expanding beverage leadership • 670+ wholesale accounts • 80% of retail revenue tied to members • Portfolio
Slide 7: Footprint & Portfolio of Assets
FOOTPRINT & PORTFOLIO OF ASSETS 3 190 K 1 16K 2 5 2 107 K 33K 180K No. of dispensaries Cultivation & Processing (sq ft) (PA facility under management) 7
Slide 8: Wholesale: Driving Our Brand Momentum
WHOLESALE: DRIVING OUR BRAND MOMENTUM STRONG PERFORMANCE • Wholesale accounted for 44% of 2Q 2026 revenue BRAND PENETRATION • 85% penetration across core states for trailing 12 months thru 2Q 2026 STRATEGIC DISTRIBUTION • Product placements in >670 dispensaries across 6 states • Licensing third-part
Slide 9: A Portfolio of Top-Selling Brands
A PORTFOLIO OF TOP-SELLING BRANDS* • Betty’s Eddies - #1 edible in MA, MD & DE • Bubby’s Baked - #1 baked goods edible in MA, MD & IL • Vibations Drink Mix – Top 10 beverage in MA, MD & IL • InHouse – Top 10 gummy in MA, MD & DE • Nature's Heritage - #1 flower brand in DE *based on BDSA and Lit Aler
Slide 10: Continuing to Expand Across Core Markets
CONTINUING TO EXPAND ACROSS CORE MARKETS Wholesale Revenue (in millions USD) Doors Coverage Ratio $80.0 800 Growth Rate $69.6 692 $70.0 $62.9 700 620 $60.0 600 $50.0 $48.8 500 410 $40.0 $32.9 400 $30.0 300 $20.0 200 $10.0 100 $0.0 26% 48% 29% 11% - 55% 83% 85% 2022 2023 2024 2025 2023 2024 2025 85%
Slide 11: Strong Retail Experience
STRONG RETAIL EXPERIENCE STRONG RETAIL BRAND & PRESENCE • 13 dispensaries across MA, IL, MD, DE, and OH • Strong presence under unified Thrive retail brand, app, and website CONSUMER EXPERIENCE • Curated, wellness-focused retail environments with premium design • Deep community engagement with veter
Slide 12: Strong Loyalty Member Growth
STRONG LOYALTY MEMBER GROWTH Members (Thousands) 450 Growth 402 415 400 364 Data-Driven Personalization Delivered: 342 350 316 • Membership +31% year over year growth 300 in Q2 2026 250 • Drove 80% of retail revenue in Q2 2026 200 • 1% higher avg basket vs non-members 150 in Q2 2026 100 50 0 7% 8% 7
Slide 13: Management Team
MANAGEMENT TEAM Jon Levine Timothy Shaw Howard Schacter CEO & President Chief Operating Officer Chief Communications Officer Co-founder of MariMed with two Oversees all cultivation, production, and Veteran communications leader with decades in the cannabis industry. Led retail operations across 9 st
Slide 14: Our Results: Q2 2026 Financial Performance
OUR RESULTS: Q2 2026 FINANCIAL PERFORMANCE
Slide 15: Q2 2026 Financial Results
Q2 2026 FINANCIAL RESULTS Revenue & Brand Momentum • Revenue increased 6% year over year to $41.9 million, Revenue $41.9 million despite ongoing industry pricing pressure across several core markets • Wholesale revenue grew 8% year over year, representing GAAP Gross Margin 38.7% 44% of total revenue
Slide 16: Balance Sheet - End of Q2 2026
BALANCE SHEET - END OF Q2 2026 Capital Structure • Total assets of $197.2 million versus total liabilities of $147.1 million as of quarter-end Cash and Cash Equivalents $8.4 million • Total debt of $78.8 million represented approximately 40% of total assets • Balance sheet capacity continues to supp
Slide 17: Q2 2026 YTD Cash Flow
Q2 2026 YTD CASH FLOW Cash Flow Category Q2 2026 YTD Activity Positive cash flow Operating Activities $3.168 million from operations Capital expenditures and license Investing Activities -$1.260 million renewals/purchases ~$2.3 million in scheduled Financing Activities -$2.355 million debt and finan
Slide 18: Year-end Non-GAAP Supplemental Information
Year-end Non-GAAP Supplemental information Income (loss) from Operations to Adjusted EBITDA Reconciliation (in ‘000s USD) 2020 2021 2022 2023 2024 2025 Income (loss) from operations 14,440 26,535 19,879 14,269 2,609 (2,820) Depreciation of property and equipment 1,792 2,098 3,432 5,549 7,910 8,109 A
Slide 19: Q2 2026 Non-GAAP Supplemental Information
Q2 2026 Non-GAAP Supplemental information (in ‘000s USD, except where noted) GAAP Income from operations 418 Depreciation of property and equipment 2,331 Amortization of acquired intangible assets 717 Stock-based compensation 350 Severance 16 Acquisition-related and other 116 Adjusted EBITDA 3,948 G
Slide 20: Q2 2026 Non-GAAP Supplemental Information
Q2 2026 Non-GAAP Supplemental information (in ‘000s USD, except where noted) GAAP Net loss (3,571) Stock-based compensation 350 GAAP Gross margin 38.7% Amortization of acquired intangible assets 717 Severance 16 Amortization of acquired 1.3% Acquisition-related and other 116 intangible assets Non-GA
Slide 21: Thank You
THANK YOU For more information: Email: ir@marimedinc.com